Recently, the 2026 Industry King Global Intellectual Property Ecosystem Conference, hosted by IPR Daily, officially announced the "Industry King" honor list, and Xuanzhu Biopharma Technology Co., Ltd. was successfully selected.

With "IP Business Value Creation" as its core positioning, this year's conference comprehensively evaluated companies' patent layout, technological innovation, and global intellectual property operation capabilities around three core indicator systems: scale dimension, quality dimension, and value dimension. Since deeply cultivating the innovative drug track, Xuanzhu Biopharma has focused on Class 1 innovative drugs in the anti-tumor and digestive fields, built a global patent protection system, simultaneously advanced overseas rights licensing, and constructed an intellectual property operation system covering the entire chain from R&D to commercialization. Its comprehensive strength received high recognition from the organizing committee.

"Industry King"

Outstanding Enterprise in Biomedical Intellectual Property

Being selected for the "Industry King" list this time is an authoritative affirmation by the industry of the company's intellectual property strategy, original R&D capabilities, and global industrial layout. In the future, Xuanzhu Biopharma will continue to strengthen the cultivation of high-value patents and the commercialization transformation of intellectual property, build innovation barriers with independent core patents, empower innovative drug R&D through a comprehensive intellectual property system, and create a biopharmaceutical innovation enterprise with global competitiveness.

About Xuanzhu Biopharma

Xuanzhu Biopharma (Stock Code: 02575.HK) is an innovative pharmaceutical company rooted in China with a global vision, focusing on major disease areas such as digestion, oncology, and non-alcoholic steatohepatitis, and dedicated to the R&D, production, and commercialization of Class 1 new drugs with core independent intellectual property. The company has a first-class R&D team, and its core personnel all have many years of new drug R&D experience. As an emerging commercialization-oriented innovative drug company driven by R&D and empowered by AI, the company has formed a product pipeline rare in China that simultaneously covers multiple types such as small molecule chemical drugs, large molecule biologics, and antibody-drug conjugates. Guided by unmet clinical needs, the company is committed to developing into a first-class innovative drug enterprise with independent R&D, production, and sales capabilities.